American Heart Association and co-investors Philips and UPMC to fund pioneering healthcare products and solutions for patients, scientists and providers through Cardeation Capital venture capital fund
With cardiovascular disease on the rise and costs heading to $1 trillion in the U.S., ground-breaking developments in diagnostics, treatments and care are urgently needed. To assure that effective innovations are rapidly introduced into the healthcare system to benefit patients and with evidence to demonstrate their impact, the American Heart Association, together with Philips and UPMC, today announced the launch of Cardeation Capital, a $30 million collaborative venture capital fund designed to spur healthcare innovation in heart disease and stroke care. Managed by Aphelion Capital, each of the three organizations has committed $10 million to the fund to bring products and solutions to market that address critical areas of healthcare delivery and health management.
Cardeation Capital will invest in emerging healthcare companies that can measurably impact the prevention and treatment of cardiovascular diseases and stroke and their risk factors, including diabetes. Aphelion Capital, a leading healthcare and medical technology venture capital firm, brings substantial medical and health system knowledge and extensive networks to enhance returns for the fund and the entrepreneurs in whom the fund invests over the long term.
